AU2005299473B2 - Therapeutic and delivery methods of prostaglandin EP4 agonists - Google Patents

Therapeutic and delivery methods of prostaglandin EP4 agonists Download PDF

Info

Publication number
AU2005299473B2
AU2005299473B2 AU2005299473A AU2005299473A AU2005299473B2 AU 2005299473 B2 AU2005299473 B2 AU 2005299473B2 AU 2005299473 A AU2005299473 A AU 2005299473A AU 2005299473 A AU2005299473 A AU 2005299473A AU 2005299473 B2 AU2005299473 B2 AU 2005299473B2
Authority
AU
Australia
Prior art keywords
colitis
prodrug
prostaglandin
mammal
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005299473A
Other languages
English (en)
Other versions
AU2005299473A1 (en
Inventor
Robert M. Burk
Yariv Donde
John E. Donello
Todd S. Gac
Daniel W. Gil
Mark Holoboski
Wha Bin Im
Karen M. Kedzie
David W. Old
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AU2005299473A1 publication Critical patent/AU2005299473A1/en
Application granted granted Critical
Publication of AU2005299473B2 publication Critical patent/AU2005299473B2/en
Priority to AU2012227306A priority Critical patent/AU2012227306A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2005299473A 2004-10-26 2005-10-24 Therapeutic and delivery methods of prostaglandin EP4 agonists Ceased AU2005299473B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012227306A AU2012227306A1 (en) 2004-10-26 2012-09-25 Therapeutic and delivery methods of prostaglandin EP4 agonists

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62242204P 2004-10-26 2004-10-26
US60/622,422 2004-10-26
PCT/US2005/038303 WO2006047476A2 (en) 2004-10-26 2005-10-24 Therapeutic and delivery methods of prostaglandin ep4 agonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012227306A Division AU2012227306A1 (en) 2004-10-26 2012-09-25 Therapeutic and delivery methods of prostaglandin EP4 agonists

Publications (2)

Publication Number Publication Date
AU2005299473A1 AU2005299473A1 (en) 2006-05-04
AU2005299473B2 true AU2005299473B2 (en) 2012-06-28

Family

ID=35840538

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005299473A Ceased AU2005299473B2 (en) 2004-10-26 2005-10-24 Therapeutic and delivery methods of prostaglandin EP4 agonists

Country Status (7)

Country Link
US (1) US20080132543A1 (https=)
EP (1) EP1805139A2 (https=)
JP (1) JP2008518013A (https=)
AU (1) AU2005299473B2 (https=)
BR (1) BRPI0518242A2 (https=)
CA (1) CA2585367A1 (https=)
WO (1) WO2006047476A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006052893A2 (en) * 2004-11-08 2006-05-18 Allergan, Inc. Substituted pyrrolidone compounds as ep4 agonists
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
EP2120962A1 (en) * 2006-12-18 2009-11-25 Allergan, Inc. Methods and compositions for treating gastrointestinal disorders
WO2010108028A2 (en) 2009-03-19 2010-09-23 Fate Therapeutics, Inc. Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
WO2011047048A1 (en) 2009-10-14 2011-04-21 Gemmus Pharma, Inc. Combination therapy treatment for viral infections
ES2654994T3 (es) 2010-08-12 2018-02-15 Fate Therapeutics, Inc. Terapia mejorada con células madre y precursoras hematopoyéticas
US20120259413A1 (en) * 2011-04-07 2012-10-11 Allergan, Inc. Devices, compositions and methods utilizing ep4 and ep2 receptor agonists for preventing, reducing or treating capsular contracture
ES2769270T3 (es) 2011-09-30 2020-06-25 Bluebird Bio Inc Compuestos para transducción viral mejorada
EP2785350B1 (en) 2011-12-02 2018-05-02 Fate Therapeutics, Inc. Improved methods of treating ischemia
JP6220791B2 (ja) 2011-12-02 2017-10-25 フェイト セラピューティクス，インコーポレイテッド 増強された幹細胞組成物
WO2014150602A1 (en) 2013-03-15 2014-09-25 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
US9943545B2 (en) 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
AU2014305843B2 (en) 2013-08-09 2019-08-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
IL261002B2 (en) 2016-02-12 2024-07-01 Bluebird Bio Inc Vcn enhancer compositions and methods of using the same
WO2017139561A1 (en) 2016-02-12 2017-08-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
EP4706758A3 (en) 2019-05-21 2026-05-06 Ardelyx, Inc. Methods for inhibiting phosphate transport
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5052047A (https=) * 1973-07-12 1975-05-09
EP0287036A2 (en) * 1987-04-13 1988-10-19 Ono Pharmaceutical Co., Ltd. New pharmaceutical compositions comprising esters or amides as active ingredients
EP0985663A1 (en) * 1998-04-16 2000-03-15 Ono Pharmaceutical Co., Ltd. A 3.7-dithiaprostanoic acid derivative
EP1097922A1 (en) * 1998-07-15 2001-05-09 Ono Pharmaceutical Co., Ltd. 5-thia-omega-substituted phenyl-prostaglandin e derivatives, process for producing the same and drugs containing the same as the active ingredient
US20020002140A1 (en) * 2000-01-14 2002-01-03 Holick Michael F. Novel bisphosphonates and uses thereof
US6586468B1 (en) * 1998-09-14 2003-07-01 Ono Pharmaceutical Co., Ltd. ω-substituted phenyl-prostaglandin E derivatives and drugs containing the same as the active ingredient
EP1417975A1 (en) * 2001-07-23 2004-05-12 Ono Pharmaceutical Co., Ltd. REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP sb 4 /sb AGONIST AS THE ACTIVE INGREDIENT
US20040102499A1 (en) * 2001-06-14 2004-05-27 Allergan, Inc. EP4 agonists as agents for lowering intraocular pressure
US20040157901A1 (en) * 2003-02-11 2004-08-12 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
US20050222094A1 (en) * 2001-06-14 2005-10-06 Burk Robert M Treatment of inflammatory bowel disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1339678E (pt) * 2000-11-27 2007-11-30 Pfizer Prod Inc Agonistas selectivos do receptor ep4 no tratamento de osteoporose
ES2254726T3 (es) * 2001-07-16 2006-06-16 F. Hoffmann-La Roche Ag Analogos de prostaglandina como agonistas receptores de ep4.
CA2478653A1 (en) * 2002-03-18 2003-09-25 Pfizer Products Inc. Methods of treatment with selective ep4 receptor agonists
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
RU2311409C2 (ru) * 2003-01-10 2007-11-27 Ф.Хоффманн-Ля Рош Аг Производные 2-пиперидона в качестве агонистов простагландина
JP5319065B2 (ja) * 2003-02-11 2013-10-16 アラーガン インコーポレイテッド 眼圧降下剤としての１０，１０−ジアルキルプロスタン酸誘導体

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5052047A (https=) * 1973-07-12 1975-05-09
EP0287036A2 (en) * 1987-04-13 1988-10-19 Ono Pharmaceutical Co., Ltd. New pharmaceutical compositions comprising esters or amides as active ingredients
EP0985663A1 (en) * 1998-04-16 2000-03-15 Ono Pharmaceutical Co., Ltd. A 3.7-dithiaprostanoic acid derivative
EP1097922A1 (en) * 1998-07-15 2001-05-09 Ono Pharmaceutical Co., Ltd. 5-thia-omega-substituted phenyl-prostaglandin e derivatives, process for producing the same and drugs containing the same as the active ingredient
US6586468B1 (en) * 1998-09-14 2003-07-01 Ono Pharmaceutical Co., Ltd. ω-substituted phenyl-prostaglandin E derivatives and drugs containing the same as the active ingredient
US20020002140A1 (en) * 2000-01-14 2002-01-03 Holick Michael F. Novel bisphosphonates and uses thereof
US20040102499A1 (en) * 2001-06-14 2004-05-27 Allergan, Inc. EP4 agonists as agents for lowering intraocular pressure
US20050222094A1 (en) * 2001-06-14 2005-10-06 Burk Robert M Treatment of inflammatory bowel disease
EP1417975A1 (en) * 2001-07-23 2004-05-12 Ono Pharmaceutical Co., Ltd. REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP sb 4 /sb AGONIST AS THE ACTIVE INGREDIENT
US20040157901A1 (en) * 2003-02-11 2004-08-12 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AKAMATSU K et al. Int. J of Pharmaceutics, vol. 155 (1), 1997, pp. 65-74. *
ANDERSON, BRADLEY D. et al. J. Pharmaceutical Sci. vol. 69 (4), pp. 424-430. *
CHOURASIA M. K. et al. J. of Delivery & Targeting of Therapeutic Agents, vol. 11 (2), 2004, pp. 129-148. *
FRIEND D. R. et al. J. of Controlled Release, vol. 15 (1), 1991, pp. 47-54. *
KABASHIMA K et al. J. of Clinical Investigation, vol. 109 (7), 2002, pp. 883-893. *
KAJINO HIROKI et al. Pediatric Research, vol. 56 (4), pp. 586-590. *
MARUYAMA T et al. Bioorganic & Medicinal Chemistry, vol. 10, 2002, pp. 2103-2110. *
YOSHIDA K et al. Proceedings of the National Academy of Sciences of the United States of America, vol. 99 (7), pp. 4580-4585. *

Also Published As

Publication number Publication date
JP2008518013A (ja) 2008-05-29
CA2585367A1 (en) 2006-05-04
US20080132543A1 (en) 2008-06-05
WO2006047476A3 (en) 2006-09-28
EP1805139A2 (en) 2007-07-11
BRPI0518242A2 (pt) 2008-11-11
AU2005299473A1 (en) 2006-05-04
WO2006047476A2 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
AU2005299473B2 (en) Therapeutic and delivery methods of prostaglandin EP4 agonists
AU2007233285B2 (en) Prostaglandin EP4 agonists
AU763668B2 (en) 5-Thia-omega-substituted phenyl-prostaglandin E derivatives, process for producing the same and drugs containing the same as the active ingredient
US6372730B1 (en) 2-decarboxy-2-phosphinico Prostaglandin F analogs
US7893107B2 (en) Therapeutic methods using prostaglandin EP4 agonist components
EP1814848B9 (en) 2,3,4-substituted-cyclopentanones as therapeutic agents
EP1812387B1 (en) 2,3,4-substituted cyclopentanones as therapeutic agents
EP1817033A1 (en) Treatment of inflammatory bowel disease
US7994195B2 (en) Therapeutic substituted piperidone compounds
EP1871381B1 (en) Therapeutic substituted cyclopentanones
US7772392B2 (en) Therapeutic substituted β-lactams
AU2012227306A1 (en) Therapeutic and delivery methods of prostaglandin EP4 agonists
US20100063303A1 (en) Therapeutic compounds
AU2005304764B2 (en) Substituted pyrrolidone compounds as EP4 agonists

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired